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1. Introduction 
Diabetic nephropathy is the most common cause for end-stage renal disease (ESRD). 
Chronic renal failure is associated with miscellahous alterations in carbohydrate and insulin 
metabolism.. Moreover, several specific therapies employed in renal insufficiency also 
influence pharmacological therapy of diabetes in uraemic patients.. In patients with  
altered renal function, therapeutic possibilities are limited due to the accumulatin of some 
oral agents and/or their metabolites at the reduced glomerular filtration rate (GFR). The 
connection between kidney and insulin metabolism is well known for many years (Horton 
et al, 1968). For insulin metabolism the kidneys are one of its target organs. Chronic renal 
failure is associated to multiple alterations in the carbohydrate and insulin metabolism that 
should be taken into account when treating diabetic patients with altered renal function 
(DeFronzo et al, 1973). Specific therapeutic needs (oral agents or insulin) will be determined 
based on the degree of insulin resistance or insulin deficiency of patients with renal 
insufficiency (Rabkin e al,1984). A good metabolic control is not only important in the early 
phase of diabetic nephropathy but also in diabetic patients with ESRD. It was shown in 
several studies, that metabolic control under antidiabetic therapy is a predictor for 
prognosis of patents with renal replacement therapy (Morokia et al, 2001). A good glycemic 
control can reduce the progression of atherosclerosis (Oomichi et al, 2006) and improve the 
survival in patients treated with hemodialysis (Kovesdy et al, 2008). Though, in a recent 
study it was suggested that aggressive glycemic control cannot be routinely recommended 
for all diabetic hemodialysis patients on the basis of reducing mortality risk (Williams et al, 
2010). The majority of uremic type 2-diabetic patients need insulin, however, a smaller part 
of these diabetic patients can also be treated with oral antidiabetic agents. 
The problem of the topic of this study is the fact, that there are only few data in the literature 
concerning antidiabetic therapy in type 2 diabetic patients with ESRD (Biesenbach et al, 
2010). This paper offers a review of the relevant findings related to insulin therapy in 
diabetic patients with ESRD. Additionally, we review the relevant aspects related to oral 
antidiabetic therapy in diabetic patients with impaired renal function.  
2. Insulin metabolism and insulin therapy 
The insulin metabolism is changed in uremic patients. In insulin-treated diabetic patients 
suffering from renal insufficiency the insulin requirement is reduced in renal insufficiency. 
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Additionally, hemodialysis influences insulin metabolism and the glycemic control under 
antidiabetic therapy. In this overview the insulin metabolism in uremic patients and the 
insulin therapy as well as oral antidiabetic therapy will be discussed.  
2.1 Insulin metabolism in uremic patients  
Insulin is a polypeptide hormone (51-amino acids), the molecular weight of approximately 
6000 Da, The Half-life (t1/2) of insulin is short (3–5 min). Under fasting conditions the 
insulin secretion rate is 0.5–1 unit/h. After meal insulin secretion shows a 3–10 fold increase 
(Polonsky et al 1986). In healthy subjects insulin is secreted into the portal system, insulin 
passes through the liver, where about 75% is metabolized, with the remaining 25% 
metabolized by the kidneys. About 60% of the insulin in the arterial bed is filtered by the 
glomerulus, and 40% is actively secreted into the nephric tubules. Most of the insulin in the 
tubules is metabolized into amino acids, and only 1% of insulin is secreted intact (Mak et 
al,´l992). As parameter for endogenous insulin secretion C-peptide can be used. Unlike 
insulin, C-peptide is not metabolized during its first pass through the liver and, 
approximately 70% of its plasma clearance is performed in the kidney (Block et al, 1972) 
For diabetic patients receiving exogenous insulin, renal metabolism plays a more 
significant role since there is no first-pass metabolism in the liver. As renal function starts 
to decline, insulin clearance does not change appreciably, due to compensatory 
peritubular insulin uptake. But once the GFR drops below 20-30mL/min, the kidneys 
clear significantly less insulin, an effect causally determined by a decrease in the hepatic 
metabolism of insulin that occurs in uremia. Despite an increase in insulin resistance 
caused by renal failure, the net effect is a reduced requirement for exogenous insulin in 
ESRD as the result of periodic improvement in uremia, acidosis, and phosphate handling 
(Shrishrimal et al, 2009). 
Thus, in the presence of impaired renal function, the type 1 as well as type 2 diabetic 
patients require less insulin, mainly due to prolonged insulin clearance (Biesenbach et al, 
2003). For these reasons the American College of Physicians recommends to decrease insulin 
doses by 25% of initial insulin dose when GFR is 50-10 ml/min and by 50% when GFR is 
less than 10 ml/min (Aronoff et al 1999). Other factors that contribute to decreasing 
exogenous insulin requirements in CRF diabetic patients are the reduction of renal 
gluconeogenesis, uraemia-induced anorexia and weight loss (Charpentier, et al, 2000) 
In ESRD, both uremia and dialysis can complicate glycemic control by affecting the 
secretion, clearance, and peripheral tissue sensitivity of insulin. Several factors, including 
uremic toxins, may increase insulin resistance in ESRD, leading to a blunted ability to 
suppress hepatic gluconeogenesis and regulate peripheral glucose utilization. In type 2 
diabetes without kidney disease, insulin resistance leads to increased insulin secretion. This 
does not occur in ESRD because of concomitant metabolic acidosis and vitamin D deficiency 
(Shrishlrimal et al, 2009).Impairment of renal function is associated with insulin resistance, 
this resistance can be improved by start of hemodialysis (Rabkin et al, 1984) Hemodialysis 
alters insulin secretion,insulin clearance, and resistance. 
In an own study the mean decrease of required insulin dose dependent on time was slightly 
lower in type 1 diabetes with 2,8 IU/year versus 3.8 IU/year in type 2 diabetes (NS). The 
decline in insulin requirement increased significantly when GFR decreased below 30 
ml/min.  
The reduction of insulin requirement at the beginning of decline of renal function may be 
explained by study associated improvement of glycemic control.  
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We also measured C-peptide at the beginning and the end of renal function impairment, the 
mean difference was not significant with 2.2 versus 2.7 ng /ml, Thus, we assumed that 
residual insulin secretion has no significant impact on the reduction in insulin requirement 
dependent on GFR Insulin therapy in patients on hemodialysis is associated with 
hyperinsulinemia and a higher incidence of hypoglycaemia compared to patients without 
dialysis (Loipl et al, 2005). In rare cases insulin substitution can be stopped in type 2 diabetic 
patients with already low insulin requirement already in the pre-dialysis phase.    
2.2 Practical managing of insulin therapy in patients on hemodialysis 
Most type 2 diabetic patients with ESRD need insulin therapy. In patients with renal 
insufficiency it may be considered that intensive insulin therapy can help to improve 
glycaemic control more than conservative insulin therapy. There is lack of relevant 
pharmacokinetic studies for the various types of insulin in patients with different degrees of 
renal insufficiency (Snyder & Berns, 2004): Due to the absence of comparative studies there 
are no therapeutic guidelines that define insulin adjustments based on GFR (Bilous et al, 
2004). In hemodialysis patients with type 2 diabetes insulin requirements is usually reduced 
in probable relationship with an improvement in insulin resistance associated with the 
dialytic procedure (Schmidtz et al, 1984). Additionally, a reduced insulin clearance may 
contribute to the decrease in requirement of insulin. On the basis of evidence, it can be 
recommend a basis-bolus insulin regime with the long-acting insulin glargine (Lantus®) or 
detemir (Levemir®) for basal requirements, along with a rapid-acting insulin analogue such 
as lispro (Humalog®), insulin aspart (NovoLog®. Novorapid®) or insulin glulisine 
(Apidra®) before meals. Duration of action of insulin glargine is significantly longer than 
that of human NPH insulin (IProtaphan®, Basal®), Humulin®) with a less pronounced peak 
of action (Iglesias et al, 2008). In the literature the Tmax averages were 8.6 hours for insulin 
glargine compared to 5.4 hours for NPH insulin. Lower FPG (fasting plasma glucose) levels 
with fewer episodes of hypoglycemia are achieved with insulin glargine compared to NPH 
insulin. Insulin glargine is metabolized at the carboxyl terminal of the B chain to two 
metabolites ) with activity similar to that of human insulin (Ersoy et al, 2006). Few studies 
were published comparing analogue insulin and regular insulin (Aisenpreis et al, 1999). 
Both, short acting as well as long acting insulin analogues have advantages in comparison to 
regular insulin. During the last years in most centers the NPH insulin was replaced by the 
long acting insulin analogues glargine or detemir. Meanwhile, several studies have 
described the use of insulin analogues in ESRD (O’Mara et al, 2010). Nevertheless, clinical 
efficacy and safety profile of insulin analogues are not clearly defined in chronic renal 
failure. Since of potentially carcinogenic and proliferative effects have not yet been 
disproved. Most studies with analogues to date have excluded diabetic patients with 
advanced diabetic complications. Therfore, there is little information regarding the use of 
these analogues in renal insufficiency. The main advantage of the short-acting insulin 
analogue is the shorter absorption, the most important advantage of the long-acting insulin 
analogues is the lower risk of hypoglycemia, thus improving glycemic control and 
improving quality of life (Jehle et al, 1999). In insulin-treated type 2 diabetic patients with 
low insulin requirement (<20 IU/day) a conventional insulin regime may such also be used, 
such as daily 1-2 injections of a long acting insulin or a pre-mixed insulin-combination 
(NPH-insulin and normal insulin or short-acting insulin analogues). When GFR decreases 
to10-50 mL/min, the total dose of both, regular insulin or insulin analogue should be 
reduced by 25%. In patients with ESRD, the insulin dose should be reduced by 50%. 
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However, there are great interindividual differences in the decrease of insulin requirement 
(Biesenbach et al, 2003)  
The insulin requirement in hemodialysis patíents in dialysis is very different. In an own 
study we investigated the insulin requirement during the first dialysis year in insulin-
treated type 2 diabetic patients dependent on rest diuresis. Patients were divided into two 
groups according to their diuresis. Group 1, of patients with preserved near-normal urine 
production (>1 l/day) during the first dialysis year (n = 12), and group 2, of patients with 
significant reduction of urine excretion (<0.5 l/day) within 3 months after start of dialysis (n 
= 12). All patients were dialysed three times per week (total dialysis time 12 h weekly). The 
HbA1c- were similar in both groups and did not significantly change during the first year. 
Insulin requirement in the patients with normal diuresis decreased from 24 IU/day at the 
start of dialysis to 14 ± 8 IU/day 1 year later (41% reduction, P < 0.05). In the group with 
reduced diuresis, the required insulin dose remained the same with 28 ± 12 and 26 ± 8 
IU/day, respectively (7% reduction). We concluded that in insulin-treated diabetic patients 
the insulin requirement can be different due to differences in the residual renal function. 
During the first year hemodialysis the insulin requirement can further drop in patients with 
decreasing diuresis (Biesenbach et al, 2008). However, the evidencce of this study limited 
due to the small patient groups. 
The targets of therapy in patients with ESRD are similar as in subjects with normal GFR; The 
targets are a hemoglobin A1c value between 6% and 7%, a fasting blood glucose level less 
than 140 mg/dL, and a postprandial glucose level less than 200 mg/dL. The individual 
targets of therapy may be changed depending on the higher risk for hypoglycemia in 
patients on hemodialysis (Uzu et al, 2008) 
3. Oral antidiabetic drug therapy 
Type 2 diabetic patients with ESRD need in the majority insulin therapy, however, some 
patients are treated by oral anti-diabetic drugs or diet alone. In type 2 diabetes and terminal 
renal failure several drugs can be used. Nevertheless, Most oral antidiabetic drugs are not 
recommended under hemodialysis therapy. 
3.1 Old oral antdiabetic drugs 
Three “old” agents have been approved for patients with renal insufficiency. 
Sulfonylurea (SU) drugs can be used in diabetic patients with ESRD (Charpentier et al, 
2009): Gliquidone (Glurenorm®) can be used with normal dose, gliclazide (Diamicron®) 
and glimepiride (Amaryl®) in reduced dose (50%). Under hemodialysis SU drugs should 
rather be avoided due to the higher risk of hypoglycaemia. Glibenclamid (Euglucon®)is 
absolutely contraindicated in renal insufficiency due to severe hypoglyceimia (Krepinsky et 
al, 2000).  
Alpha-glucosidase inhibitors 
Both, the alpha-glucosidase inhibitor acarbose (Glucobay®) and especially miglitol 
(Diastabol®) are contraindicated in ESRD (Yale 2005) 
Biguanides 
Metformin (Glucophage®, Diabetex®, Metformin®) is a biguanide that reduces hepatic 
gluconeogenesis and glucose output. It is contraindicated in patients with renal disease  
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(s-creatinine >1.1 mg/dl in women and >1.4 mg/dl in men) and also in congestive heart 
failure due to the risks of lactic acidosis. However, in some studies the authors suggestsed 
that the use of metformin in patients who are over the age of 80 years, have congestive heart 
failure or have renal insufficiency leads to a benefit that far outweighs the potential harm. 
(McCormack et al, 2005) 
3.2 New antidiabetic drugs  
In this group three “new”agents are included: insulin secretizers (glinide), insulin sensitizers 
(glitazone) and the new group of GLP 1 agonists and DDP inhibitors (gliptine) (Mohideen et 
al, 2005)  
Meglitinides  
The are two glinides,: repaglinide (Novonorm®; Prandin®) and nateglinide (Starlix®) are 
insulin secretagogues, both can be used in renal failure, but not recommended for patients 
on hemodialysis (Nagai et al, 2003) 
Thiazolidinedione (glitazone) 
Pioglitazone (Actos®) do not need dosing adjustment. Main adverse effect of this agents is 
edema, therefore it is contraindicated in heart failure, especially when combined with 
insulin therapy. Since the end of 2010 only pioglitazone is available. Rosiglitazone 
(Avandia®) was removed due to an increased cardiovascular risk (Thompson-Culkin et al, 
2002) 
Incretine (GLP-1 Analogues and Gliptins)  
Glucagon-like peptide-1 (GLP-1) stimulates glucose-dependent insulin release from 
pancreatic beta cells and inhibits inappropriate postprandial glucagon release. It also slows 
gastric emptying and reduces food intake. Dipeptidyl peptidase IV (DPP-IV) is an active 
ubiquitous enzyme that deactivates a variety of bioactive peptides, including GLP-1. 
Exenatide (Byetta®) is a naturally occurring GLP-1 analogue that is resistant to degradation 
by DPP-IV and has a longer half-life. Given subcutaneously, no dose adjustment is required 
if the glomerular filtration rate (GFR) is greater than 30 mL/min, The drug's label has been 
updated to note that the drug should not be used in patients with severe renal impairment;  
Exenatide is absolutely contraindicated in patients on hemodialysis (Kuehn, 2011) 
Sitagliptin (Januvia®) was the first oral DPP-IV inhibitor, the usual dose of sitagliptin is 100 
mg once daily, with reduction to 50 mg for patients with a GFR of 30 to 50 mL/min, and 25 
mg for patients with a GFR < 30 mL/min (Bergman et al, 2007). Further vildagliptin 
(Galvus®), normal dose 2x50 mg daily, a dose reduction is recommended for patients with 
moderate to severe renal impairment (Thuren et al, 2008).  
4. Fluctuation of blood glucose and monitoring of glycemic control 
Several factors can negatively influence glycaemic control in diabetic patients. These include 
poor food intake, insufficient exercise, uraemia-induced anorexia, insulin metabolism 
disorders, especially insulin resistance and reduced insulin clearance, and inadequate drug 
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4.1 Fluctuations of blood glucose under hemodialysis 
High fluctuations of blood glucose (BG) are characteristically in insulin-dependent diabetic 
patients on hemodialysis. Several factors contribute to these wide fluctuations in BG-levels 
and increase the risk of hypoglycemic events. Hemodialysis may cause hypoglycemia due to 
a decrease of plasma glucose and immunoreactive insulin. Patients undergoing 
hemodialysis may become hypoglycemic and not be aware of it. There is no hormonal 
imbalance causing the hypoglycemia and the hormonal response to the hypoglycemia is 
blunted. Patients with an initial plasma glucose of 5.5 mmol/l (100 mg/dl) or less who are 
hemodialyzed and who do not eat during dialysis may be particularly at risk, especially if 
they are on insulin or taking glucose-lowering medication. These should be dialyzed with a 
dialysis fluid containing at least 5.5 mmol/l (100 mg/dl) glucose. (Jackson et al, 2000). In 
patients with poor metabolic control, hyperglycemia appears immediately post-
hemodialysis; this was attributed partly to the hemodialysis-induced decrease in the plasma 
immunoreactive insulin levels. In summary, hemodialysis causes hypoglycemia during 
dialysis and hyperglycemia post-dialysis by absolute or relative plasma immunoreactive 
insulin deficiency (Shrishrimal, 2009). The dextrose concentration in the dialysate can affect 
glucose control in both ways. Dialysates with lower dextrose concentrations may be 
associated with hypoglycemia, dialysates with higher dextrose can lead to hyperglycemia. 
Most dialysis centers are using dialysate with 100mg/dl glucose concentration Furthermore, 
there it was reported that hypoglycemia is usual at the day following hemodialysis, the 
authors recommended a reduction of the basal insulin dose at these days. Recent study has 
demonstrated a significant 25% reduction in basal insulin requirements the day after 
dialysis compared to the day before. No significant change in bolus insulin was oserved, 
and overall the reduction of total insulin requirements was −15% (Sobngwi et al, 2010) 
Insulin in peritoneal dialysis 
The fluctuations of blood glucose, hyperinsulinemia and the rare formation of insulin 
antibodies under subcutaneous insulin (sc) injection can be prevented by peritoneal dialysis 
PD). Investigations of insulin in patients treated with PD indicate that the intraperitoneal 
(ip) administration on of insulin leads to more even glucose levels, but that when dialysis 
fluids with glucose concentrations higher than 13.6 g/L are used, the absorption of glucose 
from the abdominal cavity is greater in PD with ip insulin treatment than it is with sc 
administration (Quellhorst, 2002)  
The raised glucose absorption from the abdominal cavity in ip insulin administration must 
be regarded as a disadvantage. Investigations of insulin in PD showed, that after a dwell 
time of 30 min, the absorption of insulin from the abdominal cavity in the patients with 
diabetes was much higher than in the patients without diabetes. In several studies the 
authors compared both routes of insulin administration. they observed a better fall of 
HbA1c after switching from sc to ip administration (Grodstein et al, 1981) 
4.2 Monitoring of glycemic control 
It is well known that hemoglobin A(1c) is no exact parameter for glycemic control in uremic 
diabetic patients (Joy et al , 2002). Especially, the hemoglobin A(1c) level can be falsely high 
in ESRD, but it is still a reasonable measure of glycemic control in this population. The cause 
of the falsely evated level in diabetic patients with ESRD is the elevated blood urea nitrogen, 
which causes formation of carbamylated hemoglobin, which is indistinguishable from 
glycosylated hemoglobin. Other factors such as the shorter red life span of red blood cells, 
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iron deficiency, recent transfusion, and use of erythropoietin-stimulating agents may also 
cause underestimation of glucose control. In a recent study it was reported that glycated 
albumin is a better glycemic indicator than glycated hemoglobon values in hemodialysis 
patientswith diabetes (Inaba, eet al, 2007) However, in the clinical practise glycated 
hemoglobin was not replaced by glycated albumin or fructosamine 
5. Metabolic control and vascular diseases dependent on antidiabetic therapy 
There are only few data in the literature concerning metabolic control under different -
antidiabetic therapy. In a recent study we investigated metabolic control and vascular 
diseases in 64 type 2 diabetic patients under chronic hemodialysis therapy. 42 patients (65%)  
received insulin therapy (n=42) versus 12 patients oral antidiabetic drug therapy (19%). 10 
patients were treated with diet alone (16%). Observation period was the first year of 
hemodialysis (Biesenbach et al, 2010). The baseline data are summarized in table 1, The  
 
 Oral SU Insulin Diet alone 
Number (n) 12 42 10 
Age (years) 63+16 62+11 62+11 
Female (n/%) 6 (50%) 24 (57%) 5 (50%) 
Body weight 78+21 79+18 76+16 
Diabetes duration 
(years) 
13+4 16+5** 6+3** 
C-Peptide (ng/ml) 2.2+1.1 1.8+0.9* 2.4+1.1* 
Hypertension (n) 10 (87%) 38 (90%) 8 (80%) 
Antihypertensive 
drugs (n/%) 
2,3 (0- 4) 2,1 (0-4) 2.0 (0-3) 
Statine (n/%) 4 (33%) 14 (33%) 4 (40%) 
Smoker (n/%) 4 (33%) 12 (28%) 3 (33%) 
*p<0.05, **p<0.01 
Table 1. Baseline data before the start of hemodialysis in patients with sulfonylurea (SU) or 
insulin therapy and/or diet alone 
5.1 Metabolic control dependent on antidiabetic therapy 
HbA1c values were similar in each groups at the start of HD as well as after one year. 
Hypoglycemia occurred more frequently in the insulin-treated patients, however the 
difference was not significant. The triglycerides were significantly lower in the insulin-
treated patients (138+28 versus 176+46 mg/dl, (p<0.05). The body weight was similar in 
each group, during 12 months a slightly weight loss (1-2%) could be observed in the group 
with oral antidiabetic and insulin therapy. The metabolic control in the three patient groups 
is presented in table 2 and 3 as well as table 4.  
The C-peptide at the start of HD was lower in the insulin treated patients with 1.8+0.9 
ng/ml versus 2.2+1.1 and 2.4+1.1 ng/ml in the other groups (p<0.05). During the first 12 
months after the start of hemodialysis in the patient group with SU therapy two patients 
became insulin dependent, on the other group insulin therapy could be stopped in two 
cases, a reduction of insulin dose was necessary in 2 patients (48%). 
www.intechopen.com
 
Special Problems in Hemodialysis Patients 
 
92
 At start of HD after 12 months changes 
HbA1c (%) 7.6+1.3 7.7+1.2 + 1% 
Hypo (n/patient/month) 0.6 0.9 +50% 
Body weight (kg) 78+21 76+18 -2% 
Cholesterol (mg/dl) 168+44 156+33 -7% 
Triglycerides (mg/dl) 188+48 176+46 -6% 
SU gliclazid/glimerpirid (n) 6/6 4/4  
SU changed to insulin (n) 0 2 16% 
SU changed to diet alone (n) 0 2 16% 
Table 2. Metabolic control at the start and after 12 months hemodialyis in patients with 
sulfonylurea (SU) as oral antidiabetic therapy. 
 
 
 At start of HD after 1 year changes (%) 
HbA1c (%) 7.9+1.1 7.7+0.8 -2%   
Hypoglycemia 
(n/patient/month) 
0.6 1.1 +83% 
Body weight (kg) 79+18 78+17 -1% 
Cholesterol (mg/dl) 154+42 144+36 -6% 
Triglycerides (mg/dl) 144+38 138+28 -4% 
Insulin dose 
(U/patient/day) 
28+6* 22+5* -21% 
Insulin changed to SU (n) 0 1 8% 
Insulin changed to diet 
alone (n) 
0 1 8% 
*p<0.05 




 At the start of HD after 1 year changes (%) 
HbA1c (%) 7.4+0.8 7.1+0.6 -4% 
Hypoglycemia 
(n/patient/month) 
0,4 0,6 +50% 
Body weight (kg) 76+16 76+12 0% 
Cholesterol (mg/dl) 182+38 178+33 -3% 
Triglycerides 
(mg/dl) 
164+32 160+33 -3% 
Diet alone changed 
to insulin 
0 0 0% 
Diet alone changed 
to antidiabetic drug 
0 1 10% 
Table 4. Metabolic control at the start and after12 months hemodialysis in patients with 
diabetes diet alone. 
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5.2 The prevalence of vascular diseases depended on antidiabetic therapy 
The prevalence of vascular diseases was only slightly higher in the insulin-treated patients 
(NS). The prevalence of coronary artery disease was 45% in the CAD group versus 33% and 
3o% in the other two groups. This may be caused by a significantly higher diabetes 
duration. The prevalences are also shown in figure 1 The similar prevalence of 
macroangiopathy at the start of dialysis is not surprisingly, in each patient groupthe 
vascular risk factors were similar. The renal disease in type 2 diabetic patients at ESRD is in 
the majority a diabetic nephropathy (70-80%) The other diabetic patients mostly suffer from 
a vascular nephropathy (15-25%). It may be assumed that patients with vascular disease 
need more often only diet alone. In an earlier study we reported, that during the last 3 years 
before start of dialysis, progression of diabetic and vascular nephropathy with fall in GFR, 
were similar, and the prevalence of vascular diseases too (Biesenbach et al, 2006). 
Surprisingly, there is no relevant study in the literature concerning differences in the 
antidiabetic therapy between patients with diabetic and vascular nephropathy. In a recent 
study comparing the outcome of patients with diabetic and vascular nephropathy, we 
reported that insulin was used in 67% of the patients with diabetic nephropathy versus in 





















Fig. 1. Prevalence of cerebrovascular disease (CVD), coronary artery disease (CAD) and 
peripheral artery disease (PAD) dependent on anti-diabetic therapy with diet alone, Insulin 
or sulfonylurea (SU) drug. 
6. Conclusions 
Antidiabetic therapy in patients with ESRD can be difficult, both, the administration of oral 
antidiabetic drugs as well as the insulin injction. To obtain a good glycemic control in 
chronic renal insufficiency multiple factors intrinsic to diabetes, renal insufficiency and 
therapy has to be taken into account. Insulin resistance and and hyperinsulinaemia can 
impair the capacity of antidiabetic therapy. The requirement of insulin decreases in renal 
insufficiency due to reduced insulin clearance. Intensive insulin therapy is the adequate 
method for improving glycaemic control in ESRD. The most common side effect of insulin is 
hypoglycemia. In the few studies reported until now, the use of insulin analogues in uremic 
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patients has been associated with potential advantages and benefits with regard to 
glycaemic control, yet without any significant elevation in hypoglycaemic event frequency. 
Intensified insuin therapy, the basis bolus regime, shoud be prefered, in type 2 diabetes wth 
low insulin requirement a conventional insulin therapy can also be used. 
7. Summary – important factors of antidiabetic therapy in ESRD 
 Wide fluctations in blood glucose levels are characteristically in diabetic patients on 
hemodialysis 
 Most of the diabetic patients with ESRD need insulin- therapy, only a small group of  
these patients can be treated with oral antidiabetic drugs  
 Several oral antidiabetic drugs like glinide, glitazone and gliptine as well as some SU 
agents can be used in patients with renal insufficiency, in patients on hemodialysis in 
most cases a drug dose reduction by 50% is necessary in most cases. 
 Most diabetes drugs are excreted at least in part by the kidney, so that patients in ESRD 
are at greater risk of hypoglycemia 
 Impairment of renal functon is associated with reduced insulin clearance , therfore, 
insulin doses should be lowered in patients with low GFR. 
 In patients with insulin therapy hypoglycaemia occurs more frequently during dialysis 
and hyperglycemia after dialysis due to insulin deficiency- 
 The hemoglobin A1c level can be falsely high in ESRD, but there is no alternative, it is 
still a reasonable measure of glycemic control  
 The prevalence of vascular diseases is not significantly different in the the patients with 
insulin versus oral antidiabetic therapy 
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